Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

Running, not enrolling · Not applicable

Conditions studied: Breast Cancer

In brief

Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). Within the last 10 years technological advancements of -omics approaches, such as RNA-sequencing and shotgun proteomics, have dramatically reduced the cost and technical challenge of accessing these tools for discovery-based research. Investigators are now able to obtain unbiased datasets showing changes in transcript or protein expression within complex samples. With cost and accessibility of sequencing is no longer being substantial bottleneck, one of major challenges researchers now face is determining how to meaningfully interpret profiles from large datasets. The extensive characterization of molecular pathways impacting inflammatory responses, endothelial function and angiogenesis, the pathway and network analysis tools will be an asset for identification molecular pathways relevant to alterations in microvascular endothelial function. The investigators preliminary studies on only a small number of samples highlights this potential of the proposed approach to lead to identify personalized medicine-based profiles that will predict patients are likely to develop microvascular endothelial dysfunction from CTx.

Key facts

Study ID: NCT05223322
Run by: Medical College of Wisconsin
People needed: 80
Starts: 2022-03-01
Expected to finish: 2026-12-31
Last updated by the study team: 2026-07-14

Who can join

Age: 18 and older, up to 100. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Adult (≥ 18 years) assigned female sex at birth
Diagnosed with invasive non-metastatic breast cancer
Receiving neo-adjuvant CTx (or adjuvant CTx and undergoing breast conserving surgery) that includes anthracyclines (such as DOX) and/or targeted anti-Her2 therapy
Able to safely participate in moderate exercise and strength training based on MD approval
Willing to complete all study activities
Self-identifies as Black/African American or non-Hispanic White

You may not qualify if…

Unintentional weight loss > 10% in the past 6 months
Current pregnant and lactating patients. Must have completed lactation prior to study start
Metastatic disease
Diagnosed cardiovascular disease as evidenced by cardiomyopathy (reduced regional or global LV contractility), diastolic dysfunction grade 2 or above, symptomatic coronary - artery disease, ejection fraction below 50%
History of prior chemotherapy or targeted H2N Treatment received less than 3 years ago
Non-English speaking

Where it is running

University of Illinois Chicago — Chicago, Illinois, United States
Medical College of Wisconsin — Wauwatosa, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.